Tasonermin

證據等級: L5

預測適應症: 10 個

Tasonermin: From Soft Tissue Sarcoma (Isolated Limb Perfusion) to Prostatic Urethra Urothelial Carcinoma

One-Sentence Summary

Tasonermin is a recombinant TNF-alpha internationally known for use in soft tissue sarcoma via isolated limb perfusion; no formal original indication record exists in this Evidence Pack. The TxGNN model predicts it may be effective for Prostatic Urethra Urothelial Carcinoma, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure network-inference signal at this stage.

Quick Overview

Item	Content
Original Indication	Not available (no Norway/Taiwan license on record)
Predicted New Indication	Prostatic Urethra Urothelial Carcinoma
TxGNN Prediction Score	99.81%
Evidence Level	L5
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, Tasonermin (recombinant human TNF-alpha) is understood to act via TNFR1 to induce apoptosis of tumor vascular endothelium, disrupt tumor microvasculature, and activate anti-tumor immune responses, giving it theoretical broad-spectrum cytotoxic potential against solid tumors. It has an established international use in soft tissue sarcoma via isolated limb perfusion.

For the top-ranked candidate, prostatic urethra urothelial carcinoma, the repurposing rationale is purely mechanistic extrapolation: TNF-alpha's vascular-disruptive and immune-activating effects are hypothesized to be applicable to solid urothelial tumors, but there is currently no direct clinical or literature evidence connecting Tasonermin to this indication. The same pattern holds across ranks 2–10 (other urothelial carcinomas, HER2+ breast carcinoma, and several rare gynecologic adenocarcinomas) — all are network-predicted associations without supporting trials or publications.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Norway Market Information

Not marketed in Norway; no authorization records available (total_licenses = 0).

Cytotoxicity

Item	Content
Cytotoxicity Classification	Immunotherapy / biologic response modifier (recombinant TNF-alpha cytokine)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked and all subsequent predicted indications sit at Evidence Level L5 (model prediction only, no clinical trials or literature), and the drug is not marketed in Norway/Taiwan. Combined with a blocking data gap in TFDA label warnings/contraindications, there is currently no basis for advancing to safety screening or clinical evaluation.

To proceed, the following is needed:

TFDA-approved label warnings and contraindications (DG001, blocking — required before any S1 safety assessment)
Confirmed mechanism-of-action documentation from DrugBank or primary literature (DG002)
Preclinical or mechanistic studies on TNF-alpha activity in urothelial carcinoma to substantiate the mechanistic link
Route-of-administration compatibility assessment (currently marked "pending" for all candidates)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.